Skip to main content
. 2019 Jan 24;11(2):137. doi: 10.3390/cancers11020137

Figure 1.

Figure 1

Experimental model. Full-length CD200 secreted from tumor cells binds to the CD200 inhibitory receptor (CD200R1) on antigen-presenting cells, shutting down an immune response. In addition to the inhibitory receptor, the CD200 checkpoint has CD200-like activation receptors (CD200R4) that have adjuvant-like properties when stimulated; ligation with the CD200 activation receptor peptide ligand (CD200AR-L) activates an as yet undetermined signaling cascade that surmounts the inhibitory signals and allows activation of and normal antigen presentation by the antigen presenting cell. Permission by Michael R. Olin, University of Minnesota, Minneapolis, MN. Unpublished work, 2018.